MedTrace Logo

A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD

NCT01946620 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1767

Last updated 2018-10-24

No results posted yet for this study

Summary

Efficacy of Fluticasone/Formoterol in COPD Treatment. The Effect study.

Conditions

Interventions

DRUG

Flutiform

DRUG

Formoterol

Sponsors & Collaborators

  • Mundipharma Research Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-04-30
Completion
2016-05-31

Countries

  • Bulgaria
  • Germany
  • Hungary
  • Latvia
  • Lithuania
  • North Macedonia
  • Poland
  • Romania
  • Russia
  • Slovakia
  • South Africa
  • South Korea
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01946620 on ClinicalTrials.gov